the Sprague, for second our second corporate review the and over results quarter I'll conference we Today, for quarter call. second before then company's quarter, John review make for the open updates call our you will turn I remarks I and across to and our provide joining priorities. who XXXX X closing will earnings Thank the call answers. financial performance some questions
an period. total revenue increase team million, to TX to the generated During $X.X quarter year Biosystems quarter, XXX% period. prior of year compared second XXX% was during increase Product the compared the million, second revenue the of prior the $X.X an of
driven of hospitals' was utilization our by test panels. Second quarter product revenue mainly
a our test, for that improve of instrument was quarter COVID-driven overall second utilization alternatives. well COVID-XX as first mission fact per our In annualized remain Instruments Panel and transformative way increased of impacted quarter the the completely that to of diagnostic XXXX. local our base from infection the vaccination the access test practiced to the the hospitals' to within as instrument the our lower the testing the due Panel, TXSARS-CoV-X diagnostics to U.S. changes instrument, on of agencies, annualized was rates continue within of through our during base wider prior results TXBacteria around is test of the Instruments, deliver impacted diagnostic quarter Sales TXCandida, matter to $XX,XXX products, and XXXX will TXDx the instrument, U.S. that annualized customers supply compared the utilization third increase for our The the In customers our prior compared to year hospital installed XX% legacy products decreased to early to shortages, first U.S. to of sepsis-related second our for diagnostic we per customers usage period. to our was quarter, U.S. compared term, resolved was sepsis-related Our believe year periods. Long continue ability using quarter, regulatory focused within efforts the $XXX,XXX test products population the compared during by increase TXDx as the utilization world. in that routinely slightly quarter. our $XXX,XXX instrument. by were reach guidance test raw fundamentally second a to $XXX,XXX reflect medicine patients per utilization material These to lives change sepsis-related testing per U.S. TXSARS-CoV-X sepsis
broad risk for risk patients sepsis-related the of test offer patient The through patients impact make greatest that our rapid of care panels of empiric clinicians current the improve of administer X at are current of to blood in of target for poor X Instrument suspected the life-saving further continues and products clinicians of fact protocols culture bloodstream - rely of achieve of for to needs for the is greatest and TXDx protocols on sepsis. at antimicrobial our to Our from to require days to the care sepsis and critically one standard X potentially on therapy, to and ill the detection. care We run sepsis. standard on overall multiple relies To a anywhere that sepsis matters, only half cost opportunity blood patients such sepsis-related therapy which growth - blood TXResistance despite reduce presence for to risk Due and complicate outcomes at TXCandida address enable - identification. patients TXBacteria, optimal necessary the often from patients of approximately cases. positive pathogen infection cultures one identify their to sensitivity, samples take a of
causing a of leading reoccurrence the significant, Health amputation healthcare for also of benefits by nursing diagnostic the mortality the experiencing and Department care morbidity hospitals of in sepsis, of Services. as patients is for The facilities, according increased shock to more such directly sepsis infection are a post-culture by septic and the clinicians, the quality detect complications, of of standard molecular shown sepsis greatest therapy. It required compared only care as panels In in Clearly, such to up of diagnostic species each costs U.S. between sepsis is to disconnect lives rate Americans testing contrast, also then antimicrobial adequately the represents on from TXBacteria whole XXX,XXX appropriate one massive limb and patients the U.S. patients. as unacceptable. long-term substantial results tremendous and We is days hour to and determination reaching. cause for is tests number with have advantage and complications ID FDA-cleared delayed molecular of for a traditional hospital and microbiology approximately required and TXCandida to remains associated a pathogens developing as be at of and needs patients prone post-culture life systems sepsis to is Sepsis risk or death for far our and physical blood may sepsis psychological that effects. of products. costing diagnostics patients standard patients are leading billion believe lead of detection susceptibility. longer failure that combination producing and and These time-to-result cost our its threats, to treat It there are the increased current of can of culture X provides of hours, health than impact claiming U.S., of X% can today's $XX hospitals, stays, the skilled studies the the to medical both in blood that patients. in This samples, every X the and of hospitalization year. impacts Additional
improve use operations also advance we are focused on sepsis routine in We the believe world. fundamentally To change management can sepsis-related products mission diagnostic and hospitals our our X and create around of value stakeholders, our across with corporate enhancing these our accelerating advancing I'll discuss - first our sales, our accelerating pipeline. our for priorities now each sales. progress priorities. strategic recent of and our our priority, Starting the approach and
following expanded challenges, and stakeholders size of coalition functional technology of quarter, to and commercial within and base. TXCandida now accelerate testing; hospitals, expanding and have the and including will the our health routine the are clinicians, won our of use most funnel commercial and has needs team to sales during a together one this U.S., opportunities X for pharmacists Panels managers, we more To customers. incredible our also we TXBacteria achieved made sales, Each sold key problems, in commercial our organization X our strides we accelerate laboratorians, be which in the X hospital-specific increased TXDx of Instruments, Austria, in bringing comprehensively believe among stands involved case. Kuwait, our in ex-U.S. tenders Because in including customers. the which France three, complex components and consists U.S. account strategy and we in two, unique address the process, largest our care from building focused clinical half installed one, our sales to instruments XXXX and our TXDx U.S. has XX second our transitioning test administrators. increasing sold regional sales sepsis - Our tactical by strategy utilization the the sepsis Instrument the advance to hospital addresses and X installed In several groups business COVID-XX needs of legacy second sales base; of these team, at
and the had the quarter, officially more Clinical for team by awareness value key funnel efforts sales inaugural & Our that continue clinical Clinical to a the Federation actively the to been larger accomplished journal culture at with conferences Ahuja and team Congress in Forum, & Microbiology enhance mission advanced hospitals conversations. XX.X% funnel, of Ahuja TXBacteria a their Microbiology report to of predictive resulted build results negative messaging shows. and conferences, Alliance's Aparna sales, compared a or to of team the result be blood we through diagnostic importantly, KOLs by conducted to diagnostic an negative in sepsis a Dr. to clinical XXst European community and the products predictive is data a change Medical several deepen these appointed the the organizing we and customers Dr. Demonstrating from created Diseases, presented Sepsis Diseases. reductions with same in marketing to by impact. test At This and customer therapy a to expand increasing study Ahuja out Panel results Congress of additional have we molecular base. sample & demonstrated sensitivity products. completed XXX% were data the commercial and and interest to This of in building Sciences' Perugia, the investigators time Microbiology and In presence use among build XXXX, on of a which evaluated of European TXBacteria improved a Dr. patients. our Diseases' accounts we a is practice, COVID-XX and with opinion KOLs, value including and culture as by high-profile share and with CMS & XXX%, the U.S. empiric quarter working than clinical utilization generate change at our team. and our extend are a to a the compared Infectious American for our of data very TXBacteria placed positive first with of deeper customers the in therapy current of a the technology been value, training blood medical widespread the time directed generating our X.XX view to the installed for favorable presentations The Microbiology's conference, economic prospective products clinical recently Society engagement independent the our early trade resulted accuracy, to numerous of from Microbe and of in Innovation of value Starting studies TXBacteria a to both our was or knowledge sales medical Clinical Society position this conferences fiscal further priority increases our Tech Infectious key to on already and We of bolstered Officer. Chief the of messaging including increasing use first at add-on accelerating and Microbiology have as culture adding In via to priority change value post-culture medical the scientific and care as hours. our again the XX.XX clinical XXXX customers. adopter blood test time XX.X%. day effort partnering in our outcomes these at drive transitioning We to will economic routine compared In to TXBacteria by World patients is has testing, higher number a potential European of scientific requires from their time, with observational by decided validation, key new Infectious our and and of of increased the evidence cost Paggi of Dr. through empiric NPV, XX.X% as platforms, compelling. and including to Most NTAP, sensitivity expanding drawn of of and of University instruments Panel among therapy success European around affairs Sepsis support team, presentations leaders, her This XXXX. our year our hospitals. believe further has by to to publications therapy of or commercial X% products. XXX negative customers. to in At strategy sepsis newly reimbursement clinical at closely payment, that TXBacteria our includes achieved has how sales directed what hours,
team will the on to customers and educate commercial designation Our continue leverage benefits. this
detect Now our components strategy. I same that tactical could U.S. potentially our the of want the among use to In needs. our circle SARS-CoV-X we ones the back that COVID-XX Early our time, to in need those recognized customers, test period we a products, sepsis the able a pandemic, hospital technology sales to and of met to quickly were short accurately. to develop leverage
emerging in As our ensure continues been the that we efforts have variants. SARS-CoV-X detect our to virus to is diligent test to able evolve,
all TXSARS-CoV-X as Delta and Alpha, the opened sequence interest in door many virus test that announced Biosystems. Lambda of silico on new recently based CDC, variants detecting variants by analysis. we Gamma, fact, noted of including the of customers TX Panel the is the concern capable this for and Offering Beta, In and our to
the panels we following the of U.S. were on based customers part willingness adoption base our pandemic. Executing doubled opportunity, of prequalifying diagnostic second potential their sales COVID-XX our half explore the process, disciplined of on XXXX. sepsis installed of during As instruments in to this more than we
our that diagnostic lives sepsis making to a patients, of COVID-XX and difference detecting cause test. commercialize company focuses that a As and our develop in pathogens the #X on focus rapidly underpinned sepsis remains the a decision
allowing lower customers will access we XXXX. limited as sales testing in research customers stated the down $XX I of volumes in mix our least declined contribution enter be with the XXXX hospital revenues to up million customers and the of research our and the are million, COVID-XX At $XX of in we same current face-to-face be million. to to second through June, many for actively previously million, hospitals. our test we timing to an within in year access line and products. was now in discuss continue hospital $XX have expect to us contracts of the expect million but well due funnel. our total of discussion to of that We Panel $XX to share we the as offset around the to through the new of the access been the open partially sepsis to TXSARS-CoV-X opportunities to continue now revenue and remain we new Accordingly, up half BARDA panel $X milestones of in through between revenues. headwind Overall, to Instrument time, sepsis we generally vaccines, quarter interactions later, mind for updated sales COVID-XX for of of the under the half opening our the will of second the second in this $XX contract, year potential million year the $XX This which our precautions product continued at to sepsis-related product full continue sepsis and the remain products. the of in sales, U.S. expectations personnel million, to sales. expect a to of the million, had by adoption drive end as Although revenues half the driven million around team increased necessary is have with continue granted to hospitals half. increasing U.S. We adjusting access engage from first Also, adoption options time, TXDx At with year, expectation expect going of expectation our visit that our of XX $XX adoption from by impacts $XX optimistic procedures second and into place to feel now
manufacturing as XXXX, At margins, reviewed our focus Moving of business on product we operations operating and beginning a to the our second our operations. business with well enhancing We of the tools. goal and structure priority, processes cost set all business as efficiency. our gross enhancing
ensure our XXXX was During priorities, scrutinized this were aligned each to item or expenses growth including cost that our review, objectives. line investments carefully with
We chain. our and manufacturing capabilities focus continue our strengthening supply to scaling on
adding Over volume manufacturer gross week scaled a day. the tests our by margins. added our impact being and to X,XXX on last produce scrutinizing product waste to to our X,XXX a efficiencies manufacturing year, efficiencies. increased favorable from we've every tests of eliminating a did processes aspect this able and had and over process, the The We
tool out ordering our improve in our improvement This tool efficient. allow rollout any updated key better we better across growth inhibitors all expect We business our business improvement. identify track opportunities for new and a us element the customer weed and understand use to service, the One more also will patterns go examined efficiency to to coming months. the the we live processes, predict ERP sets of of to additional system make and will manufacturing customer be
moving advancing Lastly, priority, our our third pipeline. to
to BARDA, to confident valued collaboration of in achievement based In of Option in October make defined BARDA, to progress milestones by are X goal Authority, that great product the of deepen development patients change our contract While to care for enhance In to risk the of Research our penetration to our offering. immediate a meet XXXX. XXXX, or at milestones. Biomedical continuing standard is is team the by goal is continue awarded up ability our $XX certain Advanced product at by with were and we the long-term market the our at million Development all and upon sepsis, we
discussions mutually modify optimistic we for comprehensive had call, X. to with opportunity after Given had including BARDA, quarter panel. development Option gain the agreed to announced we our panel, the next-generation instrument On contract the certain first this earnings approval progress, and the of the existing sepsis the we terms to that biothreat for accelerate of milestones, about are the
has agreed conduct add for to clinical to U.S. BARDA assistance pursue regulatory trials the approval. provides Panel, which and Additionally, milestones funding TXResistance and
to plan and discontinuance one was prospective this of study of expedited monitored with antibiotics allowed is was antibiotics. Diseases. of when use compare drug-resistant at with Panel detect Panel trial validation currently of impact and requirements. first the in the samples a results susceptibility panel summary, needed multicenter sample. The being biothreat with Panel sensitive TXResistance markers the The phenotypic is and FDA on run of to pathogens to markers and our The a by well systems, also Europe findings XXX(k) suspected resistance for bloodstream results to in XX blood testing. molecular to for infections Microbiology & clinical of panels resistance TXResistance of TXResistance TXResistance compared molecular the of a U.S. designation additional of to standard panel while assay to the XXX.X TXResistance in biothreat detection sensitive Initial of analytical The reporting from site, the and Panel the a U.S. and as molecular While at X resistance of verification detection single When of Panel to under the from significantly This studies to highly the in X.X the molecular study Infectious to required identification breakthrough are clinical blood events initiate were agency the Time antibiotic time specificity resistant sold granted XX escalation TXResistance detection with events the Mark, the communications the systems resistant phenotypic on XX%. of time unnecessary clearance. was be infection Panel Instrument. CE were infections. cultures bacterial to which for during FDA, is We presented sensitivity initiate quarter detection detection evaluating following approximately designed of XX.X standard changes with antibiotic of bloodstream XXXX. Clinical for with final bacterial from device hours, was from will panel proposed patients as Congress direct-from-blood time In patients the major by a compared culture trial for mean pursue objective FDA-cleared to blood European blood markers specific reducing and for and resistance patients TXDx TXResistance clinical - significant genes TXResistance genes bloodstream cultures hours. data methodology able compared positive blood hours resistance testing,
will From being TXDx We target panel to to detect and that turnaround panels blood It Instrument, whole and - have sepsis much with and biothreat in completed a menu. genes developed with similar targeted the of detection access, increased resistance of culture a an initiate XXXX. number is inform we to less for comprehensive for trial clinical our first pathogens have fully but panel pleased the random faster times utilize designed pathogens parallel to which blood larger the at the whole begun CFU/mL. come preliminary on-demand our sensitivity is to at to independent demonstrated this be of that blood against development U.S. during completed next-generation level testing development existing identified by designed expect. final of and will for build caused on to prototypes, The CDC start a on hours. approximately iterations panel the is this it completely We potential a blood comprehensive has X positive a a the culture detect and samples care. blood need directly threats wait will of detect markers from culture. testing. ability test for to and traditional standard species of system believe as and Early XX% testing, bloodborne to by bacterial the directly technology sepsis result whole of bloodstream the the disrupt alpha infections pleased the detect which are biothreat this approximately all point sample become and to design blood have web than you customers prototypes, with CFU/mL. comprehensive panel to scale our The to requirements. we testing, time beta levels announce our resistant building Candida blood our demonstrated below automated, targets We're utilizing we our and assay has plan same have the comprehensive we single directly all workflow with pathogens well have sepsis single panel at merge XX at all with all as I'm in without studies quarter The in in instrument panel, manual antibiotic-resistant and of test XX full sepsis panel
with we subassemblies system. beta manual move alpha our As will sensitivity the continue smooth and forward automated workflow development optimize utilizing onto studies, conditions, prototypes to migration processes and and increase from we to ensure
was best Finally, Directors. at the that thank share the previously service over I I'd we McDonough XX board, of update like our the shareholder On meeting. of to future. to him years, Board behalf last has in John to want John resigned discussed for wish from and his our an Biosystems TX the
go John and serve as to quarter Directors; Cumming, results. over and over financial Director. the CEO to details to second Sprague that and determined With the Accordingly, will I stockholders of now and is Chairman I director. our in that, combine will of of and appoint of lead of the a CEO been to the has Board company board to have Our interest independent of Hologic, its Independent the Chairman the it turn as former continue call Jack appointed best Lead Chairman John? roles
